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used to aid decision making in health care. The growing use of
modeling in economic evaluations has led to increased scrutiny of the
methods used. Objective: The objective of this study was to perform a
systematic review to identify and critically assess good practice guide-
lines, with particular emphasis on contemporary developments. Meth-
ods: A systematic review of English language articles was undertaken
to identify articles presenting guidance for good practice in DAM in the
evaluation of health care. The inclusion criteria were articles providing
guidance or criteria against which to assess good practice in DAM and
studies providing criteria or elements for good practice in some areas of
DAM. The review covered the period January 1990 to March 2014 and
included the following electronic bibliographic databases: Cochrane
Library, Cochrane Methodology Register and Health Technology Assess-
ment, NHS Economic Evaluation Database, MEDLINE, and PubMedee front matter Copyright & 2015, International S
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Results: Thirty-three articles were included in this review. A practical
ﬁve-dimension framework was developed that describe the key ele-
ments of good research practice that should be considered and reported
to increase the credibility of results obtained from DAM in the evalua-
tion of health care. Conclusions: This study is the ﬁrst to critically
review all available guidelines and statements of good practice in DAM
since 2006. The development of good practice guidelines is an ongoing
process, and important efforts have been made to identify what is good
practice and to keep these guidelines up to date.
Keywords: decision-analytic modeling, good practice, guidelines,
methods, modeling.
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Decision-analytic modeling (DAM) in health care has been widely
used to synthesize clinical and economic evidence and to inform
resource allocation decisions for the purpose of allowing scarce
health care resources to be allocated more efﬁciently [1]. In simple
terms, in DAM, a model is structured to represent clinical path-
ways to examine whether an intervention, compared, for exam-
ple, with current practice, is cost-effective [2]. Building a model
requires consideration of important elements including the com-
plexity of the clinical area, the available evidence related to the
disease, as well as other issues such as the scope or boundaries of
the model, the appropriate time horizon, the perspective of the
analysis, the availability of data, and a formal synthesis of
evidence within the model [2,3]. The increasing use of DAM in
the economic evaluation of health care interventions and health
technology assessments (HTAs) requires the use of sound analytic
methods and consideration of the requirements of good practice.The aim of this study was to perform a review to identify and
critically assess good practice guidelines, highlighting areas in
which these have failed to provide recommendations, with
emphasis being given to more recent developments. In this
study, we deﬁne DAM as a method that “uses mathematical
relationships to deﬁne a series of possible consequences that
would ﬂow from a set of alternative options being evaluated” [4].Methods
A systematic review of articles written in English was undertaken
with the aim of identifying published guidelines on DAM in
health care. The following types of studies were included: guide-
lines for DAM or HTA and other published articles on good
practice in DAM. On the basis of an assessment of their title
and abstract (if available), articles were deemed potentially
relevant for inclusion if they 1) provided general guidance inociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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which to assess good practice in DAM (e.g., a checklist).
This review excluded guidelines on 1) trials or economic
evaluations alongside clinical trials, 2) other non-DAM studies
including statistical or econometric models, and 3) conference
abstracts or other non-DAM articles.Search Strategy
An initial exploratory approach was undertaken using search
terms used in a previous review [5], and this helped inform the
ﬁnal search terms used in this review. The relevant literature was
also obtained by checking the references of the included articles.
The following bibliographic databases were searched: The
Cochrane Library, Cochrane Methodology Register, Cochrane
Health Technology Assessments, NHS Economic Evaluation Data-
base, Embase, and MEDLINE. To avoid duplication, the PROSPERO
database of prospectively registered systematic reviews in health
and social care was searched for any existing or ongoing reviews
that addressed similar topics, and none was identiﬁed. This
review covered the period from January 1990 to March 2014. This
is a period that reﬂects the development of guidelines for DAM in
health care and the consolidation of good practice guidelines.Selection of Articles for Review
Titles and abstracts (if available) were screened against the
inclusion criteria to identify potentially relevant articles. In total,
33 studies, corresponding to general guidance or elements of
good practice in DAM, were included in this review. A ﬂowchart
illustrating the study selection process is shown in Figure 1. The
methodological quality of the articles included in this study was
not comprehensively assessed using formal checklists because of
the diversity of the literature included and the nature of the
review.Fig. 1 – Flow chart.Data extraction
All studies were manually searched, and data were extracted by
the ﬁrst author from each article using a data extraction form.
The data extraction form was developed to retrieve and organize
information from each article on the basis of its main topic,
model structure, model uncertainty, model transparency, and
validation. The data extraction form was developed through a
process in which the content of the articles informed the “areas”
that the data were extracted under. This approach was used to
ensure that the review did not miss any information related to
the model-building process. The data were extracted as free text
and in the form of a “yes/no” response.Results
The DAM guidelines identiﬁed in this study have responded to
the need to reﬂect on how good practice in the ﬁeld has been
deﬁned; the need to keep pace with the rapid progress in the way
that economic evaluation methodology has progressed since the
1980s; and as a means to ensure that guidelines for good practice
remain current, effective, and helpful. More comprehensive
guidelines, for example, Philips et al. [5] or the set of the
International Society for Pharmacoeconomics and Outcomes
Research and the Society for Medical Decision Making (ISPOR-
SMDM) guidelines, have been developed as part of bigger projects,
that is, an HTA project involving experts from prestigious
academic institutions or as part of a “task force,” respectively
(see the Elements of Good Practice for DAM section).
Recommendations and statements of good practice have been
proposed following the application of different methods; for exam-
ple, Philips et al.’s synthesized good practice guidance and accom-
panying checklist resulted after taking each theme and subtheme
identiﬁed in a systematic review of guidelines followed by technical
discussions among the research team of its relevance in relation to
the development of general guidelines [5]. Guidelines produced by
ISPOR-SMDM resulted from a task force consisting of expert devel-
opers and experienced users of models from academia, industry, and
government, with representation from many countries. A decision
was made to divide the DAM topic into six components and working
groups, respectively; three of these groups covered aspects relevant
to all models such as the conceptualization of a model, the
estimation of model parameters and handling of uncertainty, and
the validation of models and issues of transparency. The other three
components considered speciﬁc techniques: state-transition model-
ing, discrete event simulation, and dynamic transmission models.
The working groups produced draft reports for each section, and in
contrast to Philips et al. there was no systematic attempt to review
the literature. The ﬁrst draft of recommendations represented the
opinions of the experts in the task force, and these were posted on
the ISPOR and SMDM Web sites for comment by the general
membership of the societies. A second group of experts—again, with
broad representation of modelers and users of models—was invited
to formally review the articles. Their comments were addressed and
after receiving any additional comments and considering any further
revisions, the ﬁnal version of each article was prepared and released
to the public (see the Elements of Good Practice for DAM section).
Of the 33 articles included in this review, 15 studies provided
general guidelines for good practice or criteria in the form of a
checklist. Eighteen articles were focused on particular elements
of good practice, for example, model structure or uncertainty, or
model transparency and validation.
Elements of Good Practice for DAM
Fifteen studies provided general guidelines for good practice; 8 of
the 15 guidelines were released before 2012 [5–13], with the
Table 1 – General guidelines.
Paper ID Model structure
Author(s)/year Topic Statement
of
decision
problem/
objective
Scope/
analytic
perspective
Rationale
for
structure
Strategies
and
comparators
Model
type
Time
horizon
Disease
states/
pathways/
time to events
Cycle
length
Parsimony
Sonnenberg et al.
[11], 1994
Framework to judge
adequacy
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Sculpher et al.
[10], 2000
Framework for validity
and quality
✓ ✓ ✓ ✓ ✓ ✓
Soto [12], 2002 Checklist for decision-
analytic modeling
✓ ✓ ✓ ✓ ✓
Weinstein et al.
[13], 2003
Good modeling
practice
✓ ✓ ✓ ✓ ✓ ✓
Philips et al. [5],
2004
General guidelines ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Philips et al. [9],
2006
Framework for quality
assessment
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Canadian
Coordinating
Ofﬁce for
Health Techno-
logy [6], 2006
General guidelines in
Canada
✓ ✓ ✓ ✓ ✓
Karnon et al. [8],
2007
Modeling issues ✓ ✓
Earnshaw and
Lewis [7], 2008
Guidelines for
economic
evaluation
✓ ✓
ISPOR-SMDM
[14–20], 2012
Good research
practices
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Paper ID Identifying and synthesizing evidence
Author(s)/
year
Topic Base-
line
data
Bias in
parameter
estimates
Costs Data
identiﬁ-
cation
Data
incor-
poration
Data
modeling
Hetero-
geneity
Methodo-
logical
Para-
meter
Parameter
estimates
Stoc-
hastic
Struct-
ural
Treat-
ment
effects
Utilities
Sonnenberg
et al. [11],
1994
Framework ✓ ✓ ✓ ✓ ✓ ✓
Sculpher et al.
[10], 2000
Framework ✓ ✓
Soto [12], 2002 Checklist ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
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Weinstein et al.
[13], 2003
Good
modeling
practice
✓ ✓ ✓ ✓
Philips et al. [5],
2004
General
guidelines
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Philips et al. [9],
2006
Framework ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Canadian
Coordinating
Ofﬁce for
Health
Technology
[6], 2006
General
guidelines
✓ ✓ ✓ ✓ ✓ ✓
Karnon et al.
[8], 2007
Modeling
issues
✓
Earnshaw and
Lewis [7],
2008
Guidelines ✓ ✓ ✓ ✓ ✓ ✓
ISPOR-SMDM
[14–20], 2012
Good
research
practices
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Paper ID Model validity
Author(s)/year Topic Face/Internal/technical validity,
veriﬁcation or consistency
Cross-
validity
External
validation
Predictive
validation
Sonnenberg et al. [11], 1994 Framework to judge adequacy ✓
Sculpher et al. [10], 2000 Framework for validity and quality ✓ ✓
Soto [12], 2002 Checklist for decision-analytic
modeling
✓
Weinstein et al. [13], 2003 Methodology regarded as good
modeling practice
✓ ✓ ✓ ✓
Philips et al. [5], 2004 General guidelines ✓ ✓ ✓
Philips et al. [9], 2006 Framework for quality assessment ✓ ✓ ✓
Canadian Coordinating Ofﬁce for Health
Technology [6], 2006
General guidelines in Canada
Karnon et al., 2007 [8] Modeling issues
Earnshaw and Lewis [7], 2008 Guidelines for economic
evaluation
✓
ISPOR-SMDM [14–20], 2012 Good research practices ✓ ✓ ✓ ✓
Note. Ticks indicate the areas for which the different studies proposed statements of good practice or guidelines.
ISPOR, International Society for Pharmacoeconomics and Outcomes Research; SMDM, Society for Medical Decision Making.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 1 2 – 5 2 9516remainder making up the ISPOR-SMDM [14–20] set of guidelines.
Table 1 presents a breakdown of the elements of good practice by
the main themes of the guidance, that is, model structure,
identifying and synthesizing evidence, and model validity. These
studies provided a source of complete information on the various
stages that need to be covered in DAM. Some of the studies
constituted a list of topics that need to be checked, or questions
that modelers need to answer before constructing a model. Most
commonly, guidelines have been presented as a series of good
practice statements, starting with Weinstein et al. [13], then
Philips et al. [5,9], and more recently ISPOR-SMDM [14–20]. DAM
guidelines provide a set of principles that might lead, for
example, to an appropriate model structure or else indicators of
areas that require consideration in decision modeling [9].
To inform model construction and increase model credibility
and validity, these guidelines provide a set of principles or check-
lists or have stated the agreement of a common application [8,10–
12,15–17,19,20]. For example, guidelines have stated that model
construction is likely to be inﬂuenced by the adoption of simplifying
assumptions reﬂecting issues such as data availability and that the
design of a model should not be driven by the data at hand. Under
these circumstances, the identiﬁcation of explicit characteristics of
the disease area that affect model selection, for example, the unit of
representation, is considered important [11,12,17,19,20]. Other
aspects in model construction that arise from the application of
models to speciﬁc groups of patients or speciﬁc settings include the
scope of the model, the model perspective, choice of model type,
choice of utility structure (e.g., quality-adjusted utility scale), and
the interventions to be included in the model [10–12,17,19,20]. These
guidelines identify the characteristics of individuals as a key
element aiding the process of model selection, that is, whether a
model needs to represent individuals or groups or interactions
between individuals [19]. Furthermore, guidelines recommend that
“the appropriate model type is determined by purpose, level of
detail and complexity” [19, p. 809], and “explicit processes” involv-
ing expert consultation, inﬂuence diagrams, or other similar things
should be used to convert the conceptualization of the problem into
an appropriate model structure [19].
ISPOR-SMDM [14–20] recognized the difﬁculty for all models in
achieving all the recommended best practices for model valida-
tion, that is, face validity, internal validity, cross-validity, exter-
nal validity, and predictive validity. Instead of establishing a
minimum quality standard, guidelines recommend the adoption
of optimal practices that all models should aim for [16]. Among
these, model transparency was identiﬁed as a key area of optimal
practice that should be achieved by all models and is reﬂected by
providing clear information on how the model was built, that is,
describing its structure, parameter values, and assumptions [16].
ISPOR-SMDM [14–20] reiterated statements of good practice
emphasizing on its appropriate conduct and furthermore estab-
lishing grounds for usage, for example, the use of time horizons
sufﬁciently large to capture all health effects and costs relevant
to the decision problem in cohort simulations [14–20] or insisting
on the value of model simplicity as long as a model’s face validity
is not compromised [19].
Model Structure
Good practice for selecting a model or the use of alternative
model structures was discussed in ISPOR-SMDM [15,17,19] and in
4 of the 18 individual articles included in this review [21–24].
Model structure should be considered in the initial stages in the
process of model building (Table 2). Guidelines have suggested
that before model building, researchers should identify the
problem and objective of the project, the analytical perspective
of the model, the scope, the rationale for selecting the particular
structure, the target population, and the strategies andcomparators and then give justiﬁcation for choosing the model
type, the time horizon, and the disease states [19,21,23,24]. These
initial steps are important and will have important implications
for the model structure, data requirements, and the reporting of
ﬁnal results obtained from the model.
Guidelines for conceptualizing a model’s structure have
evolved from statements of general principles, for example, by
stating that the structure of a model should be consistent with the
theory of the health condition and the available evidence [13], to
more systematic processes describing how to select a model from
competing alternatives [21–24]. ISPOR-SMDM [15,17,19] described
the development and construction of a model as a process that
starts withmodel conceptualization [19], which consists of a two-step
process: problem conceptualization and model conceptualization.
Problem conceptualization in this context is transforming knowl-
edge of the health care process into a representation of the
decision problem. Model conceptualization is the representation
of the components of the problem using a particular decision-
analytic method (Table 2). The nature of the problem and the
project objectives are decisive in selecting the structure of a model.
Furthermore, ISPOR-SMDM [15,17,19] suggested that the early
speciﬁcation of the decision problem and project objectives will
improve model building and the structure of the model (data
requirements, analytic strategy, and reporting) [19].
The importance of the choice of model structure stems from the
fact that alternative model structures can have an impact on model
results and thereby affect decision making [19,21,23]. The appro-
priate model type should be determined according to its purpose,
level of detail required, and complexity [19]. As previously demon-
strated, guidelines aid the selection of an appropriate modeling
approach by providing an overview of competing approaches and
highlighting examples of where each alternative technique should
be used [19,21,23]. The most common issues affecting a model’s
selection are [15,17,19] as follows: 1) the unit of representation, does
a model represent individuals or groups? The unit of representation
affects the level of detail required for the variables that predict
outcomes [19]; 2) whether the decision problem requires the
modeling of the effect of an intervention on disease spread or use
of limited resources; in other words, if interactions among individ-
uals need to be represented, then models designed for patient
interactions are necessary [19]; and 3) the time horizon is dictated
by the problem scope. For example, decision trees are considered
appropriate for models with very short time horizons, whereas
longer horizons require the use of models such as state transition
(e.g., a Markov) or discrete event simulation [19].
Among the most difﬁcult stages in the conceptualization of a
model is the selection of the appropriate level of model complex-
ity because very simple models may lose face validity if they do
not incorporate all the aspects that experts feel are required,
whereas complex models may be difﬁcult to build, debug,
analyze, understand, and communicate [19]. Guidelines have
generally supported the choice of simpler models because “model
simplicity is desirable for transparency, ease of analysis, valida-
tion and description” [19], while at the same time it is recognized
that under certain circumstances, more complex models may be
needed. Consensus-based guidelines stating common grounds
for the application of more complex model structures have been
developed, that is, state-transition models, discrete event simu-
lation, and dynamic transmission models [17,18,20].
Model Uncertainty and Synthesis of Information
ISPOR-SMDM [14] and an additional 11 individual articles [25–35]
provided methodological guidelines for the analysis of model
uncertainty (methodological, structural, parameter, heterogene-
ity, and stochastic) and the use of sensitivity analysis. Step-by-
step guidelines and checklists have been developed (Table 3) to
Table 2 – Model structure.
Author(s)
and year
Area of
guidelines
Criteria for selecting a
modeling approach
Rationale for
structure
Model-based evaluation Parsimony Key recommendations
Roberts et al.
[19], 2012
Choice of
model
structure
Justiﬁed in line with policy
context and aiming to
inform resource
allocation
Whether a model
represents
individuals or groups
or interactions
between individuals
Expert consultation and
conceptualization in two
stages: problem
conceptualization and
model conceptualization
Model simplicity,
however,
preserving face
validity
Early speciﬁcation of the
decision problem,
modeling objectives, and
valuing outcomes will
improve model efﬁciency
(expert consultation,
inﬂuence diagrams,
concept mapping)
Siebert et al.
[20], 2012
Structures and
model
complexity
Whether the decision
problem requires time-
dependent parameters or
time to an event or
repeated events
Markov models can
handle memory by
creating states that
include history, but
then model
complexity
STMs are comprehensive
and powerful tools to
guide decision in health
care
Decision tree has
limited ability to
reﬂect time; then
STM seems the
simplest option
Markov model if the decision
problem has a manageable
number of health states; if
not, use an individual-
level STM
Karnon et al.
[17], 2012
Structures and
model
complexity
DES justiﬁed on model
ﬂexibility
Constraint resources;
patient’s interactions;
time dependencies
Value of DES to inform
health care decisions;
ﬂexible and able to
represent complex
behavior and interactions
between individuals
Easy representation
of complex
systems
A good choice if individuals
are subject to multiple or
competing risks
Bentley et al.
[22], 2010
Structures and
model
complexity
Subsequent event risk
dependent on prior event
history; simulation of
event or disease risks
over time; improving
validity
Recurrent events and
time dependency
The ability to incorporate
history is restricted to the
number of model health
states
Trade-off between
model bias and
model complexity
Failing to incorporate prior
event history in Markov
models would
overestimate the impact of
an intervention;
incorporate dependency by
adding states that track
event history; make
subsequent event risks
dependent on this history
Brennan et al.
[23], 2006
Choice of
model
structure
Needs to be justiﬁed Interactions between
individuals or an
individual- level
model; choice from
taxonomy of model
structures
Comparison of health
technologies and
synthesizing evidence on
costs and beneﬁts
Simplest model that
addresses
objectives and
structure of
disease and
treatment
Responsibility of developers
to select the most
appropriate modeling
approach; taxonomy grid
is a guidance
Barton et al.
[21], 2004
Choice of
model
structure
Needs to be justiﬁed Interactions vs. no
interactions between
individuals
Two distinct and
independent aspects:
mean estimate of cost-
effectiveness and
exploration of
uncertainty in the model
inputs
Simplicity (relates to
the size of the
model) is seen as
an advantage
Check dependence or
independence among
individuals; model
simplicity is an advantage;
model validation;
challenge the need for a
complex model
continued on next page
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 1 2 – 5 2 9518aid researchers in accounting for uncertainty or to identify how
uncertainty was incorporated in a model or to address special
model circumstances, for example, where the evidence is insuf-
ﬁcient to give a clear representation of the uncertainty through
parameter distributions [14,26]. The view presented by some of
the studies included in this review is that many published
models still fail to account correctly for the major sources of
uncertainty, in particular structural uncertainty, indicating that a
gap may still exist between techniques, guidelines, and what is
done in practice [26,31].
Assumptions adopted in decision models determine their
ﬁnal structure and can consider the choice of relevant compara-
tors and health states, or available clinical evidence that deter-
mines the type of adverse events, duration of treatment effects,
time dependency of probabilities, and prognostic implications of
surrogate end points or the clinical events included [14]. Struc-
tural uncertainties arise when these structural assumptions are
not formally quantiﬁed, and it is uncertain whether they accu-
rately reﬂect reality [14]. Current methods for addressing struc-
tural uncertainty include scenario analysis (presenting the
results under different model structures); model averaging (pre-
senting results of different models using different assumptions
and an average across these models); parameterization of struc-
tural uncertainty; and in the absence of data or presence of weak
data, expert elicitation to translate expert beliefs into probability
distributions [30]. Model structure plays an important role in
deﬁning the relationship between inputs and outputs to the point
that it has been recognized that structural uncertainty may be at
least as important, in terms of its impact on results, as parameter
uncertainty [14]. ISPOR-SMDM [14] highlighted the emerging
interest in calibration methods as an aid to ensure consistency
of inputs and outputs in a model. Calibration is used when data
are available to match model outputs rather than model inputs: it
is then necessary to determine parameter values that give model
results that match the data [14].
Many techniques that aim to capture the various sources of
DAM uncertainty have been developed and have evolved. There
still remain some areas, however, in which more research is
needed, such as accounting for uncertainty surrounding quality
of evidence for particular structural aspects; generalizability from
one setting to another; and the way multiple sources of evidence
should be combined (heterogeneity of parameter values from
different sources) [26]. ISPOR-SMDM [14] proposed the parameter-
ization of structural uncertainties into a model as an approach to
deal with issues around the quality of evidence; however, this
approach seems to become complex if a complete redesign/
rebuilding of the model is required (nested structures) [14]. Under
these circumstances, guidelines have stated that “where it is
impossible to perform structural uncertainty analysis, it is
important to be aware that this uncertainty may be at least as
important as parameter uncertainty” and analysts are encour-
aged to be explicit about the structural assumptions that might
impact their ﬁndings and suggest alternative assumptions for
future modeling exercises [14].
Model Transparency and Validation
Four articles discussed methods to assess the consistency or
validity of models and model transparency (Table 4) [16,36–38].
Model transparency reﬂects the extent to which a model’s struc-
ture, equations, parameter values, and assumptions can be
reviewed, and a model is considered transparent if any interested
reader with the necessary expertise who wants to evaluate the
model is able to reproduce it [16]. Model validation has been
recommended to enhance the credibility of models and as an
indicator of reliability in practice guidelines [9,16,36–38]. Model
transparency does not equal the accuracy of a model in making
Table 3 – Model uncertainty and synthesizing evidence.
Author(s)/year Area of
guideline
General principles Way of reporting Methodological
issues
Methods/
recommendations
Briggs et al. [14],
2012
Point estimate(s)
& parameter
uncertainty
Responsible reporting; use
of terminology; justify its
omission; decision
maker’s role; preferable
to parameterize
uncertainty from
structural assumptions if
possible
Use tornado diagrams,
threshold plots, or
statements of threshold
parameter to report DSA;
describe assumption(s);
report uncertainty
around calibrated
parameter(s); report EVPI
if needed
Methodological,
structural, patient
heterogeneity;
parameter
uncertainty and
stochastic
uncertainty
For structural uncertainty,
calibration approaches;
for parameter
uncertainty, DSA or PSA;
for point and interval
estimates, use CI or
distributions; reﬂect
absence of evidence
Bilcke et al. [26],
2011
Uncertainty:
Step-by-step
guide and
checklist
Formulate the decision
problem; specify sources
of uncertainty; obtain
information and
evidence; report results;
apportion uncertainty to
sources
Report choices of normative
approach(es); present
sources of uncertainty;
use distributions; assess
the most inﬂuential
sources of uncertainty;
report results of PSA
Methodological,
structural, and
parameter
uncertainty
State whether there is more
than one approach that
can be used; use
distributions; assess the
most inﬂuential sources
of uncertainty; global
sensitivity analysis; PSA
Jain et al. [31],
2011
Sensitivity
analysis
Report all sources of
uncertainty; strengths
and limitations of SA
should be acknowledged
(interactions and
correlations between
parameters)
If long-term analysis is
needed, conduct CEA
under various time
horizons; use, for
instance, tornado
diagrams, or threshold
analysis to present
results
Methodological,
structural,
parameter
Model averaging and
parameterization for
structural uncertainty;
methodological
uncertainty can be
addressed by providing
results for a “reference
case”; DSA or PSA
Groot Koerkamp
et al. [32], 2011
Uncertainty and
patient
heterogeneity
Consider range of
assumptions for the
natural course of a
disease; provide model
for every set of
assumptions instead of
using the single best
model; trade-off between
the realism of a model
and time availability
Use tornado diagrams or
threshold plots; describe
assumption(s); report
uncertainty; if the
purpose of the PSA is the
acquisition of
information to reduce
uncertainty, report EVPI
Parameter
uncertainty,
patient
heterogeneity,
stochastic
uncertainty (ﬁrst-
order uncertainty)
PSA joint uncertainty;
parameterization model
structure uncertainty;
ﬁrst-order Monte Carlo
analysis for stochastic;
DSA for parameter
uncertainty; EVPI if
needed
Jackson et al.
[30], 2011
Structural
uncertainty
Various sources: statistical
models, evidence used,
states or clinical events
represented, or treatment
strategies considered
Should be acknowledged,
assessed, and reported
Structural
uncertainty
Reference case model;
assign distributions; use
PSA; for nonparametized
uncertainties, use global
model; if lack of data,
elicit distributions
continued on next page
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Table 3 – continued
Author(s)/year Area of
guideline
General principles Way of reporting Methodological
issues
Methods/
recommendations
Strong et al. [35],
2012
How complex a
model should
be
Uncertainty in model
structure is complex; it
involves making
judgments about model’s
ability to accurately
represent a decision
problem
Most commonly by PSA;
however, it will only
quantify uncertainty
about the costs and
consequences; problem
when a model lacks
accuracy
Uncertainty about
the model input
values and model
structure
To properly represent
uncertainty about the
costs and outcomes,
structural uncertainty
must be presented;
structural uncertainty
measured with model
averaging or the
discrepancy approach
Bojke et al. [27],
2009
Structural
uncertainty
Impossible to accurately
predict mean costs and
outcomes; sources are
treatment effects and
type of model
Importance of
differentiating parameter
and structural
uncertainty: if
uncertainty can be
parameterized, then
there is parameter
uncertainty
Parameter,
methodological,
and structural
(little attention
given to structural
uncertainty)
Model selection (not
plausible); model
averaging (difﬁculty
determining posterior
distributions);
parameterizing (directly
representing uncertainty
by adding other
“uncertain” parameters)
Briggs et al. [28],
2003
Probabilistic
probabilities
over multiple
branches
If there is a need to specify
a distribution over
multiple branches at a
chance node
Have the Dirichlet
distribution speciﬁed
over multiple branches at
a chance node
Inconsistencies
performing
sensitivity
analysis if a node
has more than
two branches and
the sum of the
branching
probabilities is
different from 1
Use Dirichlet distribution, a
multivariate equivalent
of the beta distribution
Kuntz and Goldie
[33], 2002
Patient
heterogeneity
Cohorts are deﬁned on the
basis of population
characteristics;
sometimes, other
characteristics may be
overlooked (disease
incidence or progression),
causing heterogeneity
Heterogeneity bias may be
evaluated as a function of
three parameters: annual
probability of developing
the disease; RR of disease
with vs. without the
factor; baseline
prevalence of the factor
The assumption that
each health state
contains a
homogeneous
population group
does not always
hold: for instance,
in the presence of
risk factors
affecting the
chance of
developing
disease
Adjust by introducing a
heterogeneity factor;
probability of
transitioning to disease
dependent on
heterogeneity factor;
transition probabilities
average to that of the
model without
adjustment
continued on next page
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Briggs and Gray
[29], 1999
Uncertainty Study designs included
were modeling-type
based approaches
The majority included
some form of sensitivity
analysis (one-way
sensitivity analysis)
Mainly one-way SA;
5% attempted
statistical
analysis; 17%
failed to provide
any attempt to
quantify
uncertainty in
their results
Reference case
(comparability of results);
potential for ICER to vary;
avoid selective
comparison; uncertainty;
interval estimates; SA;
probabilistic nature of
reported range;
descriptive statistics;
estimate CI; present
CEAC
Andronis et al.
[25], 2009
Sensitivity
analysis
DSA requires variables and
sources to be justiﬁed; for
PSA, distributions should
be placed around all
parameters (excluded
parameters should be
justiﬁed)
Repeated analysis should
be run using different
models and methods
where uncertainties exist
Methodological and
structural
uncertainty
Univariate, multivariate,
PSA, and DSA;
distributions in line with
logical bounds; if
correlation is expected,
use joint distributions (do
not assume
independence)
Sendi et al. [34],
2002
Uncertainty and
opportunity
costs
Univariate and multivariate
SA to assess robustness;
however, SA does not
inform joint uncertainty
Alternative approaches as a
result of the intractability
of the ICER: NHB and
CEAC
ICER difﬁculty
apparent if a
distribution
extends over more
than one quadrant
NHB, however, a problem if
lambda is unknown;
CEAC, however, same
problem with lambda;
uncertainty can be
accounted for using
Bayesian methods
CEA, cost-effectiveness analysis; CEAC, cost-effectiveness acceptability curve; CI, conﬁdence interval; DSA, deterministic sensitivity analysis; EVPI, expected value of perfect information; ICER,
incremental cost-effectiveness ratio; NHB, net health beneﬁt; PSA, probabilistic sensitivity analysis; RR, risk ratio; SA, sensitivity analysis.
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Table 4 – Model transparency and validation.
Author(s)/
year
Area of
guideline(s)
Methodology Rationale for
model
transparency and
validation
Best practice Recommendations
Eddy et al.
[16], 2012
Transparency
and
validation
of models
Recommendations
on optimal
practice
Made available
model’s
nontechnical and
technical
documentation,
written in
sufﬁcient detail to
enable the reader
to evaluate a
model
Face validity of a
model’s structure,
evidence, problem
formulation, and
results;
transparency and
validation
Models are instruments to
help decision makers
answer complex
questions; model
conﬁdence and
credibility are
demonstrated by clarity
in model structure,
equations, parameters,
and assumptions, and by
subjecting models to
tests of validity
Karnon and
Vanni [37],
2011
Model
validation
Empirical
comparison
Identiﬁcation of
input parameter(s)
that produce
output that best
predict observed
data
Probabilistic
calibration of
models produced
improvements in
model’s accuracy
and reduced
uncertainty
Wide spread of model
calibration (probabilistic
calibration); a process of
validation against more
theoretically grounded
approaches is valuable
(Bayesian updating
approach)
Goldhaber-
Fiebert
et al. [36],
2010
External
model
validation
Literature review Model not compared
with independent
data
Heterogeneity in
how results of
model evaluation
are reported
Evaluation via comparison
(s) to independent
studies; structured
reporting format:
empirical study
description, baseline
characteristics, study
protocol, study
outcomes, model
outcomes, and model
consistency
Kim and
Thompson
[38], 2010
Model
validation
Use of internal,
prospective, and
external
validation
Indication of
reliability of
assumptions
adopted
A model that ﬁts all
available data
should be
generated
Model based on limited
data may not be
generalizable;
uncertainty from model
assumptions as
important as parameter
uncertainty; new model
that ﬁts all available data
should be generated;
model validation should
assess key events, rate of
accrual of events, and
absolute and incremental
costs and effects
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 1 2 – 5 2 9522relevant predictions; a transparent model may yield the wrong
answer, and vice versa, while a model may be correct and lack
transparency. Thus, transparency and validation are both neces-
sary for good practice in modeling [16].
Validation involves a set of methods for judging the accuracy
of models when making predictions. More recent guidelines have
used the terms model consistency or model validation to refer to ﬁve
types of model validity: face validity (evaluation of model struc-
ture, data sources, assumptions, and results), internal validity
(the practical model should behave as the theoretical model
predicts), cross-validity (comparison of results with other mod-
els), external validity (comparing model results and real-world
results), and predictive validity (comparing model results with
prospective observed events) [9,16].Principles and methods to enable researchers to assess model
validity have been discussed and in some cases demonstrated
[16,37,38]. Results of a study [38] established, however, that
health economic models based on limited follow-up data from
one source may not be generalizable either to longer follow-up
periods or other contexts. Furthermore, in addition to the stand-
ard considerations of uncertainty about parameter estimates, it is
important to assess the implications of model uncertainty on
results, in other words, to undertake independent model valida-
tion [16].
Best practice recommends that face validity (due to its sub-
jective nature) should be judged by people who have expertise in
the problem area, but who are impartial and preferably blinded to
the results [16]. Internal validity veriﬁes that mathematical
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 1 2 – 5 2 9 523calculations are performed correctly and are consistent with the
speciﬁcation of the model. Methods to assess internal validity
will depend on the model’s complexity, but two main stages of
internal validity involve the veriﬁcation of individual equations
and their accurate implementation. It should be noted that
internal validity does not evaluate the accuracy of model’s
predictions [16]. Cross-validity involves examining different mod-
els and comparing their results to then identify and analyze the
causes of differences and similarities in these results. External
validation compares the results of a model with actual data;
however, the difﬁculty in identifying “alternative data” has been
noted. Best practice to undertake external validation recom-
mends following a formal process to compare a model’s results
to actual event data. Guidelines provide awareness of the impor-
tant limitation that external validation can only address the parts
covered by data sources [16]. Predictive validity remains a highly
desirable type of independent model validation due to its poten-
tial ability to demonstrate the accuracy of the results obtained
from DAM. Its results, however, are potentially limited if there are
changes in the design of the study or other factors outside the
control of the study design change during the development of the
study [16].
Even though the latest guidelines [16] have provided more
detailed guidance on how best to ensure model transparency and
undertake validity checks, which reﬂect the value of concise
reporting of a model and advocate the quantiﬁcation of uncer-
tainties arising from differences in assumptions, [16] some
quandaries seem to prevail. For example, to examine external
validity, modelers are advised to use actual event data. That
same data in many instances, however, would already have been
used to parameterize the model—as guidelines suggest that the
most representative data sources should be used in developing
a model.Discussion
This review has critically compared statements of good practice
in contemporary guidelines and identiﬁed areas in which further
work may be needed. This review found that 1) good practice
guidelines have been developed and agreed; adherence to these
guidelines is considered as best practice in DAM; 2) guidelines
should be seen as tools that if followed will lead to the results
obtained being more credible; 3) there are common grounds in
the application of guidelines; and 4) some aspects of the guide-
lines related to DAM require further development, for example,
the choice of model structure, assessment of structural uncer-
tainty, and achieving predictive validity.
Common grounds have been identiﬁed for the application of
guidelines in aspects such as the speciﬁcation of a model’s
structure, the inclusion of incident cases over the time horizon
of an evaluation, the use of time horizons, parsimonious model
structure, and subgroup analysis in DAM.
Most decision problems can be conceptualized using one of
the available model types, while the choice of model structure is
unlimited. There is general acceptance of the special circum-
stances under which complex modeling needs to be taken into
consideration, while at the same time, overly complex models
should be avoided if a simpler model can accurately reﬂect all
aspects of the decision problem. More research should be under-
taken of case studies comparing the economic efﬁciency of
simple versus complex models, the use of hybrid models that
are considered to be very ﬂexible and accurate with no restriction
on how time is handled [15], and the trade-off between model
complexities versus model transparency. This should be done in
light of the advances in computing that make complexcalculations feasible and economically efﬁcient, opening the
way for the more generalized use of individual-based simulations
[15].
Whether model structure should be informed by data avail-
ability or not remains another conﬂicting aspect in DAM. Current
guidelines have argued the case for building a model ﬁrst and
then looking for the data to populate it because this strategy will
result in more appropriate and relevant model structures [19]. An
apparent drawback of this approach that has already been argued
by detractors is data availability. Alternatively, ﬁnding the data to
populate the model might be possible perhaps by adopting more
assumptions based on expert opinion [15,19]. Independent of the
assumptions adopted, the model parameters should reﬂect the
uncertainty due to the gaps in the available data, which in an
ideal world would trigger the need for value of information
analyses to show the value of this required data [14].
Structural uncertainty remains an area of controversy; an
inappropriate structure can invalidate the conclusions drawn from
cost-effectiveness analyses, while choices made when structuring
a model can signiﬁcantly affect its results and the inferences from
it. Until recently, even the deﬁnition of structural uncertainty was
a matter of dispute [27,30]; however, contemporary guidelines
have clariﬁed this concept by using an analogy with linear
regression, and it is now recommended as good practice to factor
in structural uncertainties into a model [14].
Another area in which issues have been raised has been with
model validity. Guidelines have recognized that “not all models
will be able to achieve all these best practices” [14] while the
“inability to do so does not necessarily imply a model is not
useful” [14]. Recent guidelines, however, seem to have provided a
scope for analysts to use their own discretion to solve some issues,
provided that the use of “optimal practices,” as described by
methods and recommended practice, is demonstrated [14]. Some
aspects of model generalizability demand further research because
it relies on the availability of follow-up data ideally from the same
source, and follow-up data from other sources may not be
generalizable to longer follow-up periods or to new contexts [38].
There are some areas in which there is a contradiction
between the guidelines; however, we believe that as with model
validity, these issues can be solved at the discretion of analysts. A
good example is when guidelines indicate the use of all feasible
and practical comparators [5,19]. The same guidelines indicate
that the choice of comparators is governed by the scope of the
model, which is a direct consequence of the research question. In
other words, even though a broad range of feasible strategies may
be available, the choice of comparators is expected to answer to
the decision problem. The inclusion or exclusion of potentially
relevant comparators, however, should be assessed as part of the
structural uncertainty of the model [27].
This review has found that although guidelines have been
developed and are available to aid researchers to inform the
results of their studies and, most importantly, to increase the
credibility of their results, these guidelines lack practicality due
to the extensive amount of information available and its com-
plexity. Current standards of reporting could be improved if a
single, comprehensive, user-friendly, and practical instrument is
made available to direct researchers toward the key elements of
good research practice in DAM, which should be assessed and
reported to increase the credibility of their results. We aim to
contribute toward this end by proposing a practical ﬁve-
dimension framework to assess adherence to guidelines in DAM.
The framework we propose incorporates and reﬂects much of
the evidence from this review; that is, it has synthesized all
contemporary guidelines in a checklist instrument. To ensure its
consistency, we adopted the most up-to-date and agreed guide-
line statement when components in each dimension were super-
seded or contradictory. The framework uses the following
Table 5 – Framework to assess adherence to good practice guidelines in decision-analytic modeling (DAM)
Dimension 1: Problem concept
Components of
good practice
Questions for review Yes, no,
or NA
Attributes
Decision problem Is there a written statement of the decision problem and
scope of the study?
A clear statement of the decision problem and scope would determine the interventions
and health outcomes to be measured.
Is the objective(s) of the study and model structure
consistent with the stated decision problem and scope?
They are expected to be consistent.
Analytical
perspective
Has the perspective of the model been stated? Most common perspectives are patient, health system (insurer), and society.
Target
population
Has the target population been identiﬁed? Target population should be deﬁned in terms of features relevant to the decision
(geography, patient characteristics, including comorbid conditions, disease
prevalence, and stage).
Health outcomes Are the outcomes of the model stated and consistent with
the perspective, scope, and overall objective(s) of the
model?
Health outcomes may be events, cases of disease, deaths, life-years gained, quality-
adjusted life-years, disability-adjusted life-years, or other measures important to
stakeholders and should be directly relevant to the question being asked.
Has any adverse effect of the intervention(s) been
captured?
Interventions may cause negative health consequences that need to be modeled and
discussed as part of the study’s results. The impact of assumptions regarding adverse
effects of interventions should be assessed as part of the structural uncertainty
analysis.
Comparators Is there a clear deﬁnition of the alternative interventions
under evaluation?
Usually, the choice of comparators is governed by the scope of the model. Impact of
assumptions adopted when deciding on comparators should be assessed as part of
the structural uncertainty analysis.
Is there a discussion around feasible options or justiﬁcation
for the exclusion of feasible options?
The choice of comparators affects results and should be determined by the decision
problem, not by data availability. All feasible and practical strategies as determined
by the scope of the model should be considered. Constraining the range of strategies
should be justiﬁed.
Time horizon Is the time horizon of the model justiﬁed and sufﬁcient to
reﬂect all the important differences between options?
Time horizon of the model should be long enough to capture relevant differences in
outcomes across strategies (lifetime). Time horizon is dictated by the problem scope
Dimension 2: Model concept
Components of
good practice
Questions for review Yes, no,
or NA
Attributes
Choice of model
type
Has the unit of representation been given? Usually stated in terms of groups or individuals. If groups are being modeled, most
frequently decision trees, Markov processes, or infectious disease models are the
correct choice; if individuals are being modeled, then the choice is between DES,
dynamic transmission models, or agent-based models.
Is there a need to model the interaction between
individuals in this model? Has this been discussed?
If interactions between individuals are required (when the disease or treatment
includes interactions between individuals), then DES, dynamic-transmission, or
agent-based models may be the correct choice.
Does the decision problem require a short time horizon? For simple models or problems (short time horizon, few outcomes), a decision tree may
be appropriate; time horizon should be large enough to capture all health effects and
costs directly related to the decision problem.
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Is it necessary to model time in discrete cycles? Continuously for individual STM or in discrete cycles for Markov STM; if the assumption
that transition probabilities do not depend on history is not required, then individual
STMs are an alternative; if disease or the treatment process needs to be represented
as a health state, STMs are appropriate (Markov type).
Is there a need to model competition for resources or the
development of waiting lists or queues?
If the problem requires the ability of a model to incorporate interactions between
individuals and other model parts, for example, to answer questions on resource
allocation, i.e., organ allocation for transplantation, distribution of antiretroviral
medications in resource-poor environments, then a DES may be appropriate.
Has a type of model been chosen and discussed? It is expected that studies report on the reasons for choosing a type of model.
Model structure Has the starting cohort been deﬁned by demographic and
clinical characteristics affecting the transition
probabilities or state values?
If results may vary by subgroups (age, sex, risk factors), it is advisable to report results
for different cohorts.
Have health states and transitions reﬂecting the biological/
theoretical understanding of the disease or condition
been modeled?
States should adequately capture the type of intervention (prevention, screening,
diagnostics, and treatment) as well as the intervention’s beneﬁts and harms. States
need to be homogeneous with respect to both observed and unobserved
characteristics that affect transition probabilities
Dimension 3: Synthesis of evidence
Components of
good practice
Questions for review Yes, no,
or NA
Attributes
Data sources Have transition probabilities and intervention effects been
derived from representative data sources for the decision
problem?
Most common sources of data include population-based epidemiological studies,
control arms of trials, or literature.
Have (all) methods and assumptions used to derive
transition probabilities and intervention effects been
described/justiﬁed?
Attention should be given to the use of transition probabilities and rates; conversion of
transition probabilities from one time unit to another should be done through rates
and never presented as percentages.
Have parameters relating to the effectiveness of
interventions derived from observational studies been
controlled for confounding?
If results of meta-analyses were used as data sources, then consider how potential
confounders are addressed; consider the likelihood of increased heterogeneity
resulting from residual confounding and from other biases across studies. Efﬁcacy
derived from RCT may have to be adjusted for compliance to reﬂect real-world
effectiveness. Effectiveness derived from observational studies must be adjusted for
confounding (e.g., using multivariate regression techniques or propensity scoring).
Adjustment for time-varying confounding (confounders that simultaneously act as
intermediate steps in the pathway between intervention and outcome) requires
special methods such as marginal structural analysis or g-estimation. When results
from observational studies are used in the model, causal graphs can be used to
explicitly state causal assumptions.
Has the quality of the data been assessed appropriately? Sources of data and data limitations are expected to be discussed.
Has expert opinion been used, are the methods described
and justiﬁed?
An expectation that strengths and limitations of assumptions adopted should be
included.
Utilities Are the utilities incorporated into the model appropriate? Methods used to obtain utility weights and methodology used to transform health state
estimates into quality-of-life scores.
Is the source for the utility weights referenced? Sources of data and data limitations are expected to be discussed.
Cycle length and
half-cycle
correction
Has the choice of cycle length been justiﬁed? It should be based on the clinical problem and remaining life expectancy.
Has the use of a half-cycle correction been stated? Any assumption adopted is expected to be disclosed.
continued on next page
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Table 5 – continued
Dimension 3: Synthesis of evidence
Components of
good practice
Questions for review Yes, no,
or NA
Attributes
Resources/costs Are the costs incorporated into the model justiﬁed and
sources described?
Sources of data and data limitations are expected to be discussed.
Have discount rates been reported and justiﬁed given the
target decision maker?
Patient
heterogeneity
Has patient heterogeneity been considered? For example, in a cohort model, states need to be homogeneous to observed or
unobserved characteristics affecting transition probabilities
Parameter
precision
Have mean values and distributions around the mean and
the source and rationale for the supporting evidence
been clearly described for each parameter included in the
model?
Sources of data and data limitations are expected to be discussed.
Dimension 4: Analysis of model uncertainty
Components of
good practice
Questions for review Yes, no,
or NA
Attributes
Uncertainty Have analyses of uncertainty pertaining to the decision
problem been included and reported? If not, have the
reasons been explained for its omission?
Analysis of uncertainty is expected to be included as part of DAM.
Parameter
estimation and
uncertainty
Has one-way DSA or two-way sensitivity analysis been
performed?
Tornado diagrams, threshold plots, or simple statements of threshold parameter values
are all appropriate. Uncertainty of parameters may be represented by several discrete
values, instead of a continuous range, called “scenario analyses.” It is a good practice
to include the speciﬁcation of parameter’s point estimate and a 95% CI range.
Has a PSA been included? The speciﬁc distribution (e.g., beta, normal, lognormal) as well as its parameters should
be disclosed. When PSA is performed without an accompanying EVPI, options for
presenting results include CEAC and distributions of net monetary beneﬁt or net
health beneﬁt. When more than two comparators are involved, curves for each
comparator should be plotted on the same graph.
Has correlation among parameters been assessed? Lack of evidence on correlation among parameters should not lead to an assumption of
independence among parameters.
If model calibration was used to derive parameters, has the
uncertainty around calibrated values been tested using
DSA or PSA?
Calibration is commonly used to estimate parameters or adjust estimated values such
as overall and disease-speciﬁc mortality and event incidence rates.
Structural
uncertainty
Has a discussion about the inclusion/exclusion of
assumptions affecting the structure of the model been
included?
For example: 1) health states and the strategies adopted following the recurrence of
events; 2) length of treatment effects; 3) types of adverse effects included; 4) duration
of treatment effects; 5) time dependency of probabilities (in a time-dependent utility,
the cost of delaying treatment as a function of the time a patient has remained in an
untreated acute pathological state); 6) prognostic implications of surrogate end
points; or 7) clinical events. Although these structural assumptions are not typically
quantiﬁed, it is uncertain whether they express reality accurately and for that reason
they should be assessed as part of structural uncertainty analysis.
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Other reporting
of uncertainty
analyses
Has the EVPI being measured/discussed? If the purpose of a PSA is to guide decisions about acquisition of information to reduce
uncertainty in the results, EVPI should be presented in terms of expected value of
information. EVPI is commonly reported in monetary terms using net monetary
beneﬁt or net health beneﬁts; EVPI should be reported for speciﬁed ICER thresholds.
Dimension 5: Model transparency and validation
Components
of good
practice
Questions for review Yes,
no, or
NA
Attributes
Transparency Has a graphical description of the model been provided?
Have all sources of funding and their role been identiﬁed?
Have all methods used been customized to speciﬁc
application(s) and settings?
Has the report used nontechnical language and clear ﬁgures
and tables to enhance the understanding of the model?
Have limitations and strengths been acknowledged/
discussed?
Is there any reference as to whether technical
documentation would be made available at request?
Validation Is there any evidence of model’s face validity? Can occur in several ways: the group that develop the model can appeal to members of the
modeling group, people in the same organization who did not build the model, or external
consultants. Any reader can perform his or her own evaluation. Peer review (previous to
publication).
Has internal validity been assessed? Veriﬁcation or technical validity; models should be subject to rigorous veriﬁcation and the
methods used should be described and results made available on request.
Has cross-validation been assessed? For external consistency (involves examining different models that address the same problem
and comparing their results), its meaningfulness depends on the degree to which methods
and data are independent. Modelers should search for modeling analyses of the same or
similar problems and discuss insights gained from similarities and differences in results.
Has external validity been assessed? This compares the model’s results with actual event data; a formal process needs to be
developed including identifying suitable sources of data; results of external validation
should be made available.
Has the model’s predictive validity been assessed? If feasible given the decision problem and future’s sources availability.
CEAC, cost-effectiveness analysis curve; CI, conﬁdence interval; DES, discrete event simulation; DSA, deterministic sensitivity analysis; EVPI, expected value of perfect information; ICER,
incremental cost-effectiveness ratio; NA, not applicable; PSA, probabilistic sensitivity analysis; RCT, randomized controlled trial; STM, state-transition model.
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V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 1 2 – 5 2 9528ﬁve-dimension checklist: 1) problem concept; 2) model concept;
3) synthesis of evidence; 4) analysis of uncertainty; and 5) model
transparency and validation (see Table 5). This framework does
not attempt to replace the guidelines provided by ISPOR-SMDM
2012 or any other contemporary guidelines; instead, it attempts
to serve as a reference point for the thorough consultation of
good practice guidelines.Strengths and Limitations
This study constitutes a comprehensive review of more than a
decade of developments in DAM, including the most contempora-
neous guidelines. Although this study has discussed all available
general guidelines in a single document, the breadth of this ﬁeld
determined that this review focus on aspects that are considered
general to all models (model structure, model conceptualization,
model parameters, model uncertainty, and model transparency and
validation). The exclusion criteria adopted (abstracts, posters, confer-
ence papers, and non–English-language studies) may be considered
as a limitation of this review; however, these were required to
guarantee consistency in the analysis; furthermore, a negligible
number of non–English-language studies were identiﬁed pertaining
to applied studies. Some databases such as HEED, PsychINFO, and
CINAHL were not included in this reviewmainly because we took the
view that the same references would be identiﬁed in MEDLINE or
their focus was applied research. This review does not address the
choice of data and its processing to yield suitable inputs for the
model; we took the view that this is a topic that has been extensively
developed in other ﬁelds such as epidemiology or statistics. Finally,
as stated in the previous section, this review has excluded applied
studies that are important for identifying which elements of guide-
lines pose greater challenges for analysts or correspond to deviances
from guidelines in current practice. This undoubtedly triggers the
need for future research on the adherence of current practice to
guidelines and its impact on results of decision modeling, emphasiz-
ing, for example, on issues around the reporting of uncertainty
analysis or the assessment of structural uncertainty or around areas
of increasing interest such as the practical use and feasibility of
generic models.Conclusions
The framework to judge the adequacy of decision modeling has
changed dramatically since it was ﬁrst envisioned; ISPOR-SMDM
constitutes the most contemporaneous, up-to-date, and agreed
set of good practice guidelines.Acknowledgments
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